30th Nov 2015 09:35
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Faron Pharmaceuticals